Scemblix (Asciminib Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Scemblix (Asciminib Hydrochloride) by Novartis: FDA Orange Book core substance LOE 2040-05-14 (last listed 2040-05-17), 0 AB generics, $257.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN215358 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-14
Last Listed Patent or Exclusivity Date2040-05-17
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$257.3M
2024 Medicare Part D Spend$197.2M
2024 Medicaid Spend$60.1M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 21.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.